ADGRV1

Across TCGA pan-cancer cohorts, ADGRV1 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ADGRV1 data layer compared with 22 for mass-spec protein and 11 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher ADGRV1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated ADGRV1 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

GBM, PDAC, and HNSC are the cancer types where ADGRV1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	OS	Median	All	0.233	0.610	.022	16	view →
PDAC	DFS	Median	All	0.275	1.000	.024	7	view →
HNSC	OS	Median	All	0.972	0.791	.024	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

ADGRV1–GBM (OS)

Open the GBM breakdown →